Skip to main content

Ingrid Jyssum

PhD stipendiat
https://orcid.org/0000-0003-1412-9713
Se Google Scholar profil
Se publikasjoner i PubMed

Utdanning

  • Lege (MD) ved det medisinske fakultet, Universitet i Oslo

Stilling

  • PhD stipendiat, Klinikk for revmatologi, poliklinikk og forskning, Diakonhjemmet Sykehus

Interessefelt

  • Revmatologi
  • Immundempende medisiner
  • Persontilpasset medisin
  • Terapeutisk legemiddelmonitorering
  • Vaksiner
  • Randomiserte kontrollerte studier

E-post

Denne e-postadressen er beskyttet mot programmer som samler e-postadresser. Du må aktivere javaskript for å kunne se den.

Telefon

+47 22451500

Besøksadresse

Diakonhjemmet sykehus
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postadresse

Diakohjemmet sykehus
Postboks 23 Vinderen
0319 Oslo

Prosjekter

WP6 - Langtidsoppfølging

NOR-DMARD

Det norske registeret for antirevmatiske legemidler

Prosjektleder:
Tore K. Kvien
WP2 - Presisjonsmedisin

Nor-vaC

Immunologisk respons på COVID-19 vaksine hos pasienter på immunosuppressiv behandling

Prosjektleder:
Guro Løvik Goll
WP1 - Behandlingsstudier

RA-DRUM

Terapeutisk legemiddelmonitorering hos pasienter med revmatoid artritt (RA-DRUM)

Prosjektleder:
Silje Watterdal Syversen
WP1 - Behandlingsstudier

SQUEEZE

Maksimering av effekten av reseptbelagte legemidler ved revmatoid artritt 

Prosjektleder:
Espen A. Haavardsholm

Publikasjoner

Publikasjoner hentet fra Nasjonalt vitenarkiv (NVA):

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Hassen Kared, Ingrid Jyssum, Amin Alirezaylavasani, Ingrid Marie Egner, Trung The Tran, Lisa Tietze


Frontiers in Immunology

2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen


RMD Open

2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Asia-Sophia Fumika Michaela Wolf, Kristin Reine Hammersbøen, Hilde Sofie Sager Ørbo, Sabin Bhandari, Guri Solum, Ingrid Fadum Kjønstad


EBioMedicine

2024

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Ingrid Jyssum, Johanna Gehin, Joseph Sexton, Eirik Kristianslund, Yi Hu, David Warren


Rheumatology

2023

Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

Kristin Kaasen Jørgensen, Marte Lie Høivik, Adity Chopra, Jurate Saltyte Benth, Petr Ricanek, Bjørn Allan Moum


Scandinavian Journal of Gastroenterology

2023

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Kristin H. Bjørlykke, Hilde Sofie Sager Ørbo, Anne Therese Tveter, Ingrid Jyssum, Joseph Sexton, Trung Tran


The Lancet Rheumatology

2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Ingrid Egeland Christensen, Trung Tran


RMD Open

2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Ingrid Egeland Christensen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Trung Tran, Siri Mjaaland


BMC Medicine

2022

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Trung Tran, Joseph Sexton, Sella Aarrestad Provan


Arthritis & Rheumatology

2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum, Hassen Kared, Trung Tran, Anne Therese Tveter, Sella Aarrestad Provan, Joseph Sexton


The Lancet Rheumatology

2021